Apollo Endosurgery, Inc. (NASDAQ:APEN) VP Bret Schwartzhoff acquired 9,500 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was acquired at an average price of $4.24 per share, for a total transaction of $40,280.00. Following the transaction, the vice president now directly owns 15,631 shares of the company’s stock, valued at approximately $66,275.44. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of Apollo Endosurgery, Inc. (NASDAQ APEN) opened at $4.08 on Tuesday. Apollo Endosurgery, Inc. has a 1 year low of $3.55 and a 1 year high of $21.88. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.00 and a current ratio of 2.54.
COPYRIGHT VIOLATION NOTICE: “Apollo Endosurgery, Inc. (NASDAQ:APEN) VP Bret Schwartzhoff Purchases 9,500 Shares” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/21/insider-buying-apollo-endosurgery-inc-apen-vp-purchases-40280-00-in-stock.html.
APEN has been the subject of several research analyst reports. Northland Securities restated a “buy” rating on shares of Apollo Endosurgery in a report on Friday, October 27th. Zacks Investment Research upgraded shares of Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Thursday, November 2nd. ValuEngine lowered shares of Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Roth Capital assumed coverage on shares of Apollo Endosurgery in a report on Wednesday, August 2nd. They set a “buy” rating and a $10.00 target price for the company. Finally, Craig Hallum assumed coverage on shares of Apollo Endosurgery in a report on Monday, July 24th. They issued a “buy” rating and a $11.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $9.44.
A number of hedge funds have recently made changes to their positions in APEN. Stonepine Capital Management LLC purchased a new stake in Apollo Endosurgery in the 3rd quarter worth $11,067,000. King Luther Capital Management Corp purchased a new stake in shares of Apollo Endosurgery during the 3rd quarter valued at about $2,567,000. Russell Investments Group Ltd. purchased a new stake in shares of Apollo Endosurgery during the 3rd quarter valued at about $1,288,000. Woodmont Investment Counsel LLC purchased a new stake in shares of Apollo Endosurgery during the 3rd quarter valued at about $220,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Apollo Endosurgery during the 3rd quarter valued at about $119,000. Institutional investors and hedge funds own 14.05% of the company’s stock.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related companies with MarketBeat.com's FREE daily email newsletter.